COVID Vaccines Returned $60 to $809 Per Dollar Invested
A study of 173 countries found high-income nations captured the largest economic gains from early vaccine access.
Updated on Nov. 6, 2026 in COVID-19
Live Poll
Should your government keep funding costly vaccine research during future global health emergencies?
A global study across 173 countries found COVID-19 vaccines generated economic benefits of USD 60 to USD 809 for every dollar invested. Worldwide development and delivery cost USD 79.4 billion, against estimated health and economic benefits between USD 6.43 trillion and USD 64.3 trillion.
Why it matters
The findings quantify the return on large public and private investment in vaccine development during the pandemic. They also highlight how delayed access in many low- and middle-income countries limited the gains those nations could capture.
The study modeled returns across 173 countries, with benefits ranging from USD 60 to USD 809 per dollar spent against a USD 79.4 billion global cost. The wide benefit range between USD 6.43 trillion and USD 64.3 trillion reflects uncertainty that the extraction does not explain.
The players
London School of Hygiene and Tropical Medicine
A London-based public health research institution that contributed researchers to the study.
Imperial College London
A leading British research university whose researchers co-authored the study.
New York University
A major private research university in New York whose researchers co-authored the study.
The details
Researchers compared vaccine development, manufacturing and delivery costs with years of life gained, quality of life, work productivity and averted health care costs. The study was published in PLOS Medicine and authored by researchers from the London School of Hygiene and Tropical Medicine, Imperial College London and New York University.
Timeline
Many low- and middle-income countries gained widespread vaccine access late in 2021.
Economic benefit was measured per dollar spent during the first year of vaccine rollout.
Big Picture
The unequal economic gains documented here echo the access gap that the COVAX facility was created to address for low- and middle-income nations. The study quantifies what delayed rollout cost those countries relative to wealthier peers.
The findings suggest that faster, more equitable vaccine distribution produces larger economic returns, which matters for future pandemic preparedness budgets. For individuals, the study underscores that vaccine access timing shaped the health and economic outcomes felt by different populations.
The takeaway
Investing early and equitably in vaccines delivers the strongest measurable returns, a lesson relevant to future pandemic planning. Access timing, not only vaccine availability, determined how much economic value different countries captured.
Further reading
For broader background on the pandemic's global response, see COVID-19.
Live Poll
Should your government keep funding costly vaccine research during future global health emergencies?
